Michael John Girgis

This inventor holds 10 USPTO granted patents, plus 1 CIPO patent and 5 EPO patents. Top assignees: Novartis Ag, Novartis Pharmaceuticals Corporation. Active years: 2001-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael John Girgis. Retrieved from https://idiyas.com/inventor/michael-john-girgis-g441twgf

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10

% Patents Active = 80.0

CIPO Patents = 1

EPO Patents = 5 (Patent Applications = 1)

Average Co-Inventor Count = 4.7

ph-index = 2

Forward Citations = 35(Granted Patents)

Company Filing History:

Novartis Pharmaceuticals Corporation

patents

Years Active: 2001-2023

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11642329 - Amorphous solid form of compounds containing S—N-valeryl-N- {[2'-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations (2023-05-09),

2. 11096918 - Amorphous solid form of compounds containing S—N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations (2021-08-24),

3. 9388134 - Compounds containing S-N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations (2016-07-12),

4. 8877938 - Compounds containing S-N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations (2014-11-04),

5. 8829194 - Crystalline forms of the sodium salt of (4-{4-[5-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid (2014-09-09),

6. 7572917 - Process for the manufacture of organic compounds (2009-08-11),

7. 7452999 - [object Object] (2008-11-18),

8. 6835838 - Process for the manufacture of organic compounds (2004-12-28),

9. 6740776 - Air oxidation of an aromatic aldehyde to an aromatic acid (2004-05-25),

10. 6271394 - Process for producing amino acid amides (2001-08-07),

Title: **The Innovative Contributions of Michael John Girgis**

Introduction

Michael John Girgis, an accomplished inventor based in Montville, NJ, has made significant strides in the field of pharmaceutical innovations. Holding a remarkable portfolio of 10 patents, he primarily focuses on developing compounds that offer therapeutic benefits for hypertension and heart failure.

Latest Patents

Among Michael Girgis's latest patents are inventive formulations that include an amorphous solid form of compounds containing the angiotensin receptor antagonist (ARB) valsartan and a neutral endopeptidase inhibitor (NEPi). These compounds, which comprise intricate molecular structures such as S—N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties with sodium cations, are specifically engineered for the treatment of hypertension and/or heart failure.

Career Highlights

Michael's professional journey includes significant tenures at renowned companies such as Novartis AG and Novartis Pharmaceuticals Corporation. His work has notably contributed to the advancement of therapeutic solutions in cardiovascular health, utilizing his deep understanding of compound structures.

Collaborations

Throughout his career, Michael has collaborated with notable professionals, including Mahavir Prashad and Bin Hu. These partnerships have fostered innovative approaches and enhanced research outcomes in the pharmaceutical arena.

Conclusion

Michael John Girgis stands out as an impactful inventor in the realm of pharmaceuticals, with a robust portfolio of patents that underline his commitment to improving health outcomes. His innovative contributions continue to pave the way for advancements in treating critical health conditions such as hypertension and heart failure.

Profile summary based on public USPTO records.